先天性心臟病的全球市場預測(2022年～2028年)

全球先天性心臟病的市場規模，在預測期間內預計以約9.1％大幅度的年複合成長率成長。

有先天性心臟病(CHD)的嬰兒中25％是重症CHD，重症CHD的嬰兒一般生後1年以內必須進行手術與其他的侵入性治療。已開發國家有複數產業企業導入缺陷治療的設備，以及新興國家的醫療費增加預計在預測期間內也帶來市場機會。可是，對這個疾病相關認知度低，妨礙市場成長。

本報告提供全球先天性心臟病市場相關調查分析，市場概要，各市場區隔、地區的市場分析，競爭情形，企業簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

• 調查範圍
• 分析師的洞察和目前市場趨勢

第3章 競爭情形

• 主要企業分析
• 主要策略分析
• COVID-19對主要企業的影響

第4章 市場決策要素

• 促進因素
• 阻礙因素
• 機會

第5章 市場明細

• 全球先天性心臟病市場:各缺陷類型
  • 心臟瓣膜的缺陷
  • 心臟牆的缺陷
  • 血管的缺陷
• 全球先天性心臟病市場:各診斷
  • 心臟超音波圖
  • 胸部X光
  • MRI掃描
  • 其他
• 全球先天性心臟病市場:各治療
  • 投藥
  • 置入式心臟設備
  • 導管治療
  • 空心術
  • 心臟移植
• 全球先天性心臟病市場:各終端用戶
  • 醫院、診所
  • 診斷中心
  • 其他

第6章 地區分析

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 義大利
  • 西班牙
  • 法國
  • 其他歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 全球其他地區

第7章 企業簡介

• Abbott Laboratories
• AstraZeneca Plc
• Becton Dickson & Co.
• Bio-Rad Laboratories
• Boston Scientific Corp.
• Laboratory Corporation of America Holdings(LabCorp)
• F. Hoffmann-La Roche Ltd.
• Glaxosmithkline Plc
• Janssen Pharmaceuticals, Inc.
• Medtronic
• Viatris Inc.
• Novartis Ag
• Pfizer, Inc.
• Randox Laboratories Ltd.
• Response Biomedical Corporation
• Sanofi S.A.
• Siemens Healthineers
• Thermo Fisher Scientific Inc.
• Vericel Corporation

Global Congenital Heart Diseases Market, By Defect Type (Heart Valve Defects, Heart Wall Defects, Blood Vessel Defects, By Diagnosis (Echocardiogram, Chest X-ray, MRI, and Others), By Treatment (Medications, Implantable Heart Device, Catheter Procedure, Open Heart Surgery, and Heart Transplant), End-Users (Hospitals and Clinics, Diagnostic Centers, Others), and Forecast Period 2021-2027

The global congenital heart disease market is anticipated to grow at a significant CAGR of nearly 9.1% during the forecast period. Congenital heart disease also called congenital heart defect is a condition having abnormalities in heart structure from birth time. The disease affects the heart walls, valves, and blood vessels of the heart. Its symptoms include shortness of breath, arrhythmias, cyanosis, edema, tiring quickly upon exertion. The rise in the incidences of congenital heart disease has been witnessed over the years. For instance, as per the Centers for Disease Control and Prevention (CDC), congenital heart defects (CHDs) affect nearly 1% of?or about 40,000?births per year in the US. Approximately 1 in 100 babies are born with a heart defect in the US annually.

Moreover, 25% of babies with CHD have a critical CHD. Infants with critical CHDs generally need surgery or other invasive procedures within their first year of life. Several industry participants in developed countries are expected to introduce devices for the treatment of defects, as well as an increase in healthcare spending across emerging countries, is to create opportunities in the market during the forecast period. However, a lack of awareness regarding the condition is hindering the growth of the market.

Impact Of COVID-19 Pandemic on the Global Congenital Heart Disease Market

The global congenital heart disease market was hit by the outbreak of COVID-19. The drug and device shortage during the COVID pandemic has led to an increasing focus of pharma companies' towards the delivery of drugs and devices quickly. The COVID-19 pandemic has disrupted the supply of medical devices and drugs across the globe. For instance, according to the National Institute of Health of the US, medication shortages in 2020 have been shown at 87% as compared to 2019. When contemplating the impact of the second wave of COVID-19 cases, the drug shortages may worsen. The market has impacted very little due to the continued demand for drugs and healthcare facilities during the pandemic.

Segmental Outlook

The global congenital heart market is segmented based on defect type, diagnosis, treatment, and end-user. Based on the defect type, the market is segmented into heart valve defects, heart wall defects, and blood vessel defects. Based on the diagnosis, the market is segmented into echocardiogram, chest X-ray, MRI scan, and others. Based on the treatment, the market is segmented into medications, implantable heart device, catheter procedures, open heart surgery, and heart transplant. Apart from this, by end-users, the market is segmented into hospitals and clinics, diagnostic centers, and others.

Global Congenital Heart Market Share by Treatment, 2020 (%)

Global Congenital Heart Market Share by Treatment

Catheter Segment holds the Significant Share in the Market

Among the treatment for congenital heart disease, the catheter segment held a potential share in 2020 and is also anticipated to grow during the forecast period. The catheter procedure allows doctors to repair congenital heart defects without surgically the chest and heart. Moreover, cardiac catheterization is used for the treatment of certain congenital heart diseases. It is used in conjunction with other tests such as an echocardiogram and MRI scans to diagnose heart defects. Thus, the growing demand for catheterization for the treatment of congenital heart disease is driving the market.

Regional Outlook

The market is further segmented based on regions including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, and Others0, and the Rest of the World (the Middle East and Africa, and Latin America). North America has been predicted to dominate the global congenital heart disease market due to well-established health infrastructure, technological developments, favorable government initiatives, and the significant prevalence of CHD.

Global Congenital Heart Disease Market Growth, by Region 2021-2027

Global Congenital Heart Disease Market Growth, by Region

Asia-Pacific is projected to have a considerable share in the global Congenital Heart Disease Market

Asia-Pacific is anticipated to hold a considerable market share during the forecast period. In the region, China and India are showing rapid progress. The increasing incidence and prevalence rate of congenital heart disease are the factors that are growing the market demand in the region. Additionally, the rising number of diabetic patients in the region is further propelling the market growth as congenital heart disease is common in people with diabetes. Moreover, the diabetes history in a family increases the risk of having congenital heart disease in newborns. China and India account for the highest cases of diabetes all across the globe. As per the IDF, China had the highest prevalence of diabetes (in the age range 20-79 years) in 2019 with around 116.5 million cases followed by India with around 77 million cases. By 2030, China and India are expected to maintain their first and second position globally in terms of the highest prevalence of diabetes with 140.5 million and 101.0 million cases, respectively. This, in turn, will likely result in the growing incidences of congenital heart defects in the region.

Market Players Outlook

Key players in the market include Abbott Laboratories, Boston Scientific Corp., Siemens Healthineers, Pfizer Inc., AstraZeneca Plc, Becton Dickson & Co., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers & acquisitions, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, Pfizer acquired Amplyx Pharmaceuticals, Inc. which is a privately-held company with its focus on the development of therapies for debilitating and life-threatening diseases.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global congenital heart disease market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market-entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Congenital Heart DiseaseIndustry
• Recovery Scenario of Global Congenital Heart DiseaseIndustry
• 1.1. Research Methods and Tools
• 1.2. Market Breakdown
  • 1.2.1. By Segments
  • 1.2.2. BY Region

2. Market Overview and Insights

• 2.1. Scope of the Report
• 2.2. Analyst Insight & Current Market Trends
  • 2.2.1. Key Findings
  • 2.2.2. Recommendations
  • 2.2.3. Conclusion

3. Competitive Landscape

• 3.1. Key Company Analysis
• 3.2. Key Strategy Analysis
• 3.3. Impact of COVID-19 on Key Players

4. Market Determinants

• 4.1. Motivators
• 4.2. Restraints
• 4.3. Opportunities

5. Market Segmentation

• 5.1. Global Congenital Heart Disease Market, By Defect Type
  • 5.1.1. Heart Valve Defects
  • 5.1.2. Heart Wall Defects
  • 5.1.3. Blood Vessel Defects
• 5.2. Global Congenital Heart Disease Market, By Diagnosis
  • 5.2.1. Echocardiogram
  • 5.2.2. Chest X-Ray
  • 5.2.3. MRI Scan
  • 5.2.4. Others
• 5.3. Global Congenital Heart Disease Market, By Treatment
  • 5.3.1. Medications
  • 5.3.2. Implantable Heart Devices
  • 5.3.3. Catheter Procedures
  • 5.3.4. Open Heart Surgery
  • 5.3.5. Heart Transplant
• 5.4. Global Congenital Heart Disease Market, By End-User
  • 5.4.1. Hospitals and Clinics
  • 5.4.2. Diagnostic Centres
  • 5.4.3. Others

6. Regional Analysis

• 6.1. North America
  • 6.1.1. United States
  • 6.1.2. Canada
• 6.2. Europe
  • 6.2.1. UK
  • 6.2.2. Germany
  • 6.2.3. Italy
  • 6.2.4. Spain
  • 6.2.5. France
  • 6.2.6. Rest of Europe
• 6.3. Asia-Pacific
  • 6.3.1. China
  • 6.3.2. India
  • 6.3.3. Japan
  • 6.3.4. South Korea
  • 6.3.5. Rest of Asia-Pacific
• 6.4. Rest of the World

7. Company Profiles

• 7.1. Abbott Laboratories
• 7.2. AstraZeneca Plc
• 7.3. Becton Dickson & Co.
• 7.4. Bio-Rad Laboratories
• 7.5. Boston Scientific Corp.
• 7.6. Laboratory Corporation of America Holdings (LabCorp)
• 7.7. F. Hoffmann-La Roche Ltd.
• 7.8. Glaxosmithkline Plc
• 7.9. Janssen Pharmaceuticals, Inc.
• 7.10. Medtronic
• 7.11. Viatris Inc.
• 7.12. Novartis Ag
• 7.13. Pfizer, Inc.
• 7.14. Randox Laboratories Ltd.
• 7.15. Response Biomedical Corporation
• 7.16. Sanofi S.A.
• 7.17. Siemens Healthineers
• 7.18. Thermo Fisher Scientific Inc.
• 7.19. Vericel Corporation

LIST OF TABLES

• 1. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS, 2020-2027($ MILLION)
• 2. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
• 3. GLOBAL HEART VALVE DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 4. GLOBAL HEART WALL DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 5. GLOBAL BLOOD VESSEL DEFECTS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 6. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 7. GLOBAL ECHOCARDIOGRAM INCONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 8. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 9. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 10. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 11. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 12. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 13. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 14. GLOBAL CATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 15. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 16. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 17. GLOBAL CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 18. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 19. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 20. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027($ MILLION)
• 21. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 22. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
• 23. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 24. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 25. NORTH AMERICAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 26. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 27. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
• 28. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 29. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 30. EUROPEAN CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 31. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 32. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
• 33. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 34. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 35. ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)
• 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027($ MILLION)
• 37. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DEFECT TYPE, 2020-2027($ MILLION)
• 38. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027($ MILLION)
• 39. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027($ MILLION)
• 40. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET RESEARCH AND ANALYSIS BY END-USER, 2020-2027($ MILLION)

LIST OF FIGURES

• 1. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET, 2020-2027($ MILLION)
• 2. IMPACT OF COVID-19 ON GLOBAL CONGENITAL HEART DISEASE MARKET BY SEGMENT, 2020-2027($ MILLION)
• 3. RECOVERY OF GLOBAL CONGENITAL HEART DISEASE MARKET, 2021-2027(%)
• 4. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DEFECT TYPE, 2020 VS 2027(%)
• 5. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY DIAGNOSIS, 2020 VS 2027(%)
• 6. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY TREATMENT, 2020 VS 2027(%)
• 7. GLOBAL CONGENITAL HEART DISEASE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027(%)
• 8. GLOBAL HEART VALVE DEFECTS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 9. GLOBAL HEART WALL DEFECTS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 10. GLOBAL BLOOD VESSEL DEFECTS INCONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 11. GLOBAL ECHOCARDIOGRAM IN FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 12. GLOBAL CHEST X-RAY IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 13. GLOBAL MRI SCAN IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 14. GLOBAL OTHERS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 15. GLOBAL MEDICATIONS FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 16. GLOBAL IMPLANTABLE HEART DEVICES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 17. GLOBAL CATHETER PROCEDURES FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 18. GLOBAL OPEN-HEART SURGERY FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 19. GLOBAL HEART TRANSPLANT FOR CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 20. GLOBAL HOSPITALS AND CLINICS IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 21. GLOBAL DIAGNOSTIC CENTRES IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 22. GLOBAL OTHER IN CONGENITAL HEART DISEASE MARKET SHARE BY REGION, 2020 VS 2027(%)
• 23. US CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 24. CANADA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 25. UK CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 26. FRANCE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 27. GERMANY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 28. ITALY CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 29. SPAIN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 30. REST OF EUROPE CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 31. INDIA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 32. CHINA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 33. JAPAN CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 34. SOUTH KOREA CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 35. REST OF ASIA-PACIFIC CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)
• 36. REST OF THE WORLD CONGENITAL HEART DISEASE MARKET SIZE, 2020-2027($ MILLION)